Aktuellt
SENASTE
In the past two days we have seen two key trial readouts from two of BB Biotech's core holding companies: Vertex (10% of securities) announced positive results from the Ph2 trial of its VX-548 for painful diabetic peripheral neuropathy, sending the shares up 13%. On 14 December, Moderna and Merck announced positive follow-up data from the Ph2 trial of their combination drug for patients with resected high-risk melanoma (skin cancer). Moderna shares are up 10%.
LÄS MER
